The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
The Reserve Bank of India (RBI) has cancelled the banking licence of the Paytm Payments…
Today, the internet is an important part of our daily life. We use it to…
Dabur has appointed Mr. Herjit S Bhalla as the Chief Executive Officer (CEO) of Its…
Brazil has overtaken India as the leading exporter of the corn (maize) to Bangladesh. This…
Aligarh is a well-known city in Uttar Pradesh. It is popularly called the "City of…
The recent satellite based global study has revealed that the landfill sites in the Secunderabad…